Publications by authors named "G Louvel"
Aims: FAST-Forward and UK-FAST-trials have demonstrated the safety and efficacy of five-fraction breast adjuvant radiation therapy (RT) and have become the standard of care for selected early breast cancer patients. In response to the additional burden caused by the COVID-19 pandemic, we implemented "One-Week Breast RT," an innovative program delivering five-fraction whole breast RT in a complete 5-day workflow. The primary objective of this study was to demonstrate the feasibility and safety of our program.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the combination of atezolizumab (a PD-L1 inhibitor) and stereotactic body radiation therapy (SBRT) in patients with advanced colorectal cancer (CRC) as part of the SABR-PDL1 trial.
- A group of 60 pretreated patients from five centers participated, receiving atezolizumab and follow-up SBRT, with a focus on measuring progression-free survival (PFS) and collecting immune profiling data.
- Results showed a median overall survival of 8.4 months and a PFS of 1.4 months, with the treatment being relatively well-tolerated; some patients exhibited significant responses, including stable disease and a few partial or
Stereotactic Body Radiation Therapy (SBRT) is a standard of care for many localizations but the question of the optimal fractionation remains a matter of concern. If single fraction sessions are routinely used for intracranial targets, their utilization for mobile extracranial lesions is a source of debate and apprehension. Single session treatments improve patient comfort, provide a medico-economic benefit, and have proven useful in the context of the SARS-CoV 2 pandemic.
View Article and Find Full Text PDFArticle Synopsis
- * The evaluation included 88 patients, with 51.1% using a molecularly-oriented approach, showing a higher rate of stable disease and positive response among them (25.7%) compared to non-molecularly-oriented patients (5.1%).
- * Results indicate that molecular profiling could improve outcomes for certain glioma patients, highlighting the need for larger studies to validate these findings and pinpoint ideal candidates for this strategy.